Sanofi S.A. is a French multinational pharmaceutical company headquartered in Gentilly, France, as of 2013 the world's fifth-largest by prescription sales. The company was formed as Sanofi-Aventis in 2004 by the merger of Aventis and Sanofi-Synthélabo, which were each the product of several previous mergers.
Apotex Inc v Sanofi-Synthelabo Canada Inc,  3 S.C.R. 265, is a leading Supreme Court of Canada decision on the novelty and non-obviousness requirements for a patent in Canada. The Court rejected a challenge by the generic drug manufacturer Apotex to declare Synthelabo Canada's patent for Plavix, ...
Find Sanofi US corporate information, pharmaceutical products, news, career opportunities and health resources.
Learn about working at Sanofi. Join LinkedIn today for free. See who you know at Sanofi, leverage your professional network, and get hired.
You can find answers to many of your general questions about Sanofi US on our Website. Just select a topic from the list below and click on the link for more information. For more specific requests, you can send a brief online form (noted by Image of Document Icon in the list below) to the appropriate Sanofi US contact or ...
Sanofi, a global healthcare leader focused on patients' needs, with diversified offering of medicines, consumer healthcare products, generics, animal health and human vaccines.
Sanofi-Synthelabo Inc., a pharmaceutical company, provides products for physicians and patients in the healthcare industry. It focuses on various therapeutic areas, such as cardiovascular diseases and thrombosis, diseases of the central nervous system, internal medicine, and oncology. The company was incorporated in ...
Get information, directions, products, services, phone numbers, and reviews on Sanofi-Synthelabo in Bridgewater, NJ. Discover more Offices and Clinics of Doctors of Medicine companies in Bridgewater on Manta.com.
Apr 26, 2004 ... NEW YORK (CNN/Money) - France's largest drugmaker Aventis will stay under French control after smaller rival Sanofi-Synthelabo raised its bid to $64.2 billion and turned a hostile bid into a friendly acquisition Monday. Sanofi-Synthelabo, which had launched a hostile bid for Aventis in January, was ...